COPENHAGEN, May 13 (Reuters) - Danish pharmaceutical group Lundbeck (LUN.CO) posted a surprise rise in first-quarter operating profits on Wednesday but cut its full-year profit outlook. Operating profits were 947 million Danish crowns ($173 million) compared with a year-ago 925 million and a mean forecast for 782 million in a Reuters survey of 9 analysts.
Lundbeck said it now saw full-year 2009 sales of 13.1 billion to 13.6 billion crowns and operating profit of between 2.8 billion and 3.0 billion.
The new forecast includes recently bought U.S. firm Ovation Pharmaceuticals, Inc., which Lundbeck said it was renaming Lundbeck Inc.
Lundbeck’s previous forecast, excluding Ovation, had been for full-year 2009 sales of 12 billion to 12.5 billion crowns and operating profit of between 3.0 billion and 3.2 billion. ($1=5.464 Danish Crown)